Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., No. 18-1691 (Fed. Cir. Oct. 30, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Idenix Pharmaceuticals LLC and Universita Degli Studi Di Cagliari (collectively, “Idenix”) appeal from the decision of the U.S. District Court for the District of Delaware granting judgment as a matter of law (“JMOL”) against Idenix and finding that U.S. Patent No. 7,608,597 is invalid for lack of enab lement. Idenix Pharm. LLC v. Gilead Scis., Inc., 2018 WL 922125, at *25 (D. Del. Feb. 16, 2018) (“JMOL Opinion”).